Clinical Trial Update: A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease [Phase 2]

View source ↗

Summary

Phase 2 safety, tolerability, and efficacy study of BMN 190 (cerliponase alfa) in pediatric patients under 18 with CLN2 disease has completed, with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Batten Disease
• Infantile Neuronal Ceroid Lipofuscinosis
• Late-infantile Neuronal Ceroid Lipofuscinosis Type

Drugs mentioned

• BRINEURA (cerliponase alfa)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Jansky-Bielschowsky Disease, Batten Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-02-17